world
popul
grown
billion
peopl
half
live
dens
popul
urban
set
travel
habit
chang
radic
number
peopl
travel
plane
grow
year
amount
total
billion
high
popul
densiti
well
extrem
increas
contact
peopl
virtual
area
world
highli
favor
global
spread
pathogen
pandem
risk
increas
climat
chang
influenc
distribut
abund
preval
pathogenbear
vector
promot
infect
rang
vectorborn
diseas
occurr
pandem
outbreak
past
decad
clearli
demonstr
realiti
global
pandem
threat
human
immunodefici
viru
hiv
caus
agent
acquir
immunodefici
syndrom
aid
repres
zoonosi
nonhuman
primat
westcentr
africa
claim
million
live
sinc
discoveri
despit
develop
effect
highli
activ
antiretrovir
therapi
haart
drug
cost
intens
access
therapi
remain
problemat
resourc
limit
set
major
infect
occur
develop
dire
need
vaccin
hiv
proven
extrem
difficult
identif
suitabl
method
gener
vaccin
remain
focu
research
influenza
virus
occur
annual
season
outbreak
howev
abil
infect
varieti
differ
speci
well
high
genom
variabl
addit
bear
constant
risk
zoonosi
introduc
viru
complet
new
immunogen
properti
human
popul
occurr
futur
influenza
pandem
almost
certain
imposs
predict
characterist
viru
sever
symptom
induc
unpredict
illustr
swine
flu
one
hand
led
phase
pandem
alert
declar
caus
rel
mild
symptom
influenza
pandem
spanish
flu
hand
result
death
around
million
peopl
current
licens
season
influenza
vaccin
specif
predefin
viral
strain
unabl
protect
futur
pandem
henc
new
vaccin
technolog
abl
induc
broad
protect
influenza
virus
urgent
requir
sever
acut
respiratori
syndrom
sar
first
occur
china
caus
novel
coronaviru
cov
like
origin
bat
sar
cov
caus
global
outbreak
infect
patient
lead
death
countri
notabl
aspect
sar
epidem
efficaci
contain
measur
halt
spread
diseas
follow
ongo
effort
develop
vaccin
sarvcov
discontinu
new
coronaviru
appear
saudi
arabia
caus
middl
east
respiratori
syndrom
mer
like
sar
cov
viru
origin
bat
like
spread
human
via
infect
dromedari
camel
accord
confirm
case
mer
death
countri
sinc
varieti
research
activ
current
ongo
develop
vaccin
mer
cov
howev
licens
vaccin
yet
avail
ebolavirus
belong
famili
filovirida
consist
two
genera
ebolaviru
marburgviru
caus
hemorrhag
fever
high
mortal
rate
whose
natur
reservoir
believ
bat
sinc
first
document
ebolaviru
outbreak
ebolavirus
emerg
period
outbreak
mostli
occur
central
african
period
attempt
develop
vaccin
ebolavirus
made
remain
research
earli
develop
stage
howev
ebola
viru
appear
west
africa
late
hit
region
heavili
affect
poverti
arm
conflict
mani
factor
among
dysfunct
health
system
contribut
inabl
control
viru
ebola
crisi
repres
first
epidem
caus
ebolaviru
case
death
late
stage
epidem
sever
vaccin
candid
test
clinic
trial
advanc
rvsvzebov
show
clinic
efficaci
ringvaccin
clinic
trial
vector
born
diseas
dengu
chikungunya
zika
transmit
speci
aed
mosquito
induc
similar
symptom
fever
sever
joint
pain
present
half
world
popul
live
area
mosquito
speci
present
infect
rate
virus
increas
dramat
last
decad
accord
case
dengu
fever
risen
past
year
zika
viru
first
identifi
nonhuman
primat
uganda
sinc
caus
sever
outbreak
differ
area
report
mild
symptom
selflimit
febril
ill
sinc
howev
outbreak
asia
america
link
sever
clinic
manifest
includ
syndrom
adult
congenit
abnorm
includ
microcephali
follow
infect
pregnanc
possibl
explan
emerg
aggrav
symptom
could
mutat
introduc
viru
allow
adapt
new
environ
result
chang
pathogen
occurr
around
one
million
laboratori
confirm
case
zika
south
america
case
microcephali
led
declar
public
health
emerg
intern
concern
pheic
februari
zika
crisi
prompt
acceler
develop
vaccin
zika
viru
seven
enter
clinic
trial
likewis
sever
clinic
trial
current
ongo
test
differ
technolog
vaccin
chikungunya
dengu
howev
except
vaccin
dengu
develop
sanofi
pasteur
vaccin
licens
diseas
note
recent
associ
increas
risk
sever
diseas
subject
never
expos
viru
april
recommend
prevaccin
screen
strategi
use
dengueseroposit
addit
pandem
threat
list
multi
drug
resist
mdr
organ
evergrow
favor
misus
overus
antibiot
hold
true
use
antibiot
human
even
problemat
anim
antibiot
routin
use
prevent
diseas
promot
growth
livestock
mdr
organ
methicillinresist
staphylococcu
aureu
mrsa
multidrugresist
tuberculosi
mdrtb
becom
seriou
threat
global
public
health
accord
estim
new
case
mdrtb
regist
could
success
treat
solut
grow
threat
could
develop
effici
vaccin
prevent
mdr
organ
spread
convent
vaccin
develop
attenu
inactiv
respect
pathogen
success
decreas
burden
number
infecti
diseas
past
lead
erad
small
pox
significantli
restrict
diseas
polio
tetanu
diphtheria
measl
howev
establish
method
may
alway
suitabl
even
feasibl
outbreak
situat
live
attenu
vaccin
gener
bear
risk
revers
render
approach
unfavor
highli
pathogen
possibl
larg
uncharacter
organ
inactiv
may
induc
protect
respons
case
ebola
even
lead
undesir
effect
like
formalininactiv
rsv
respiratori
syncyti
viru
induc
exacerb
diseas
upon
wildtyp
rsv
infect
clinic
trial
furthermor
outbreak
scenario
may
limit
convent
vaccin
develop
term
produc
sinc
method
requir
whole
pathogen
cultiv
propag
vaccin
product
may
hamper
factor
difficult
imposs
cultiv
respect
pathogen
vitro
condit
requir
high
biosafeti
level
special
lab
cultiv
henc
new
highli
versatil
approach
independ
whole
pathogen
cultiv
requir
effect
quickli
combat
outbreak
situat
order
proof
effect
upcom
pandem
new
technolog
need
overcom
number
challeng
unpredict
natur
emerg
pathogen
repres
one
pivot
problem
pandem
prepared
zoonos
present
constant
threat
introduc
previous
uncharacter
pathogen
popul
case
hiv
well
sar
mer
cov
outbreak
caus
pandem
influenza
viru
demonstr
potenti
known
pathogen
mutat
adapt
new
host
environ
unpredict
outcom
immunogen
properti
sever
symptom
induc
demonstr
recent
epidem
pandem
risk
event
highest
rna
virus
whose
high
mutat
rate
favor
adapt
sinc
vaccin
target
remain
undefin
outbreak
occur
time
remain
one
major
hurdl
effect
vaccin
develop
current
averag
develop
time
convent
vaccin
preclin
phase
year
highlight
dire
need
new
approach
allow
extrem
fast
develop
licens
prevent
emerg
outbreak
global
spread
major
problem
cost
associ
vaccin
develop
product
use
establish
technolog
develop
new
vaccin
candid
estim
amount
million
usd
expens
establish
facil
equip
rang
million
usd
cost
vaccin
develop
avoid
order
keep
requir
safeti
standard
need
dedic
product
process
facil
vaccin
convent
vaccin
technolog
keep
valid
product
cost
high
especi
consid
resourc
limit
set
ebola
crisi
fact
outbreak
situat
repres
nich
market
new
technolog
requir
support
cost
effect
vaccin
product
issu
product
capac
establish
method
often
insuffici
support
global
vaccin
even
potenti
threat
known
vaccin
manufactur
technolog
establish
like
pandem
influenza
vaccin
product
capac
meet
peak
demand
pandem
remain
problemat
thank
effort
coordin
potenti
product
capac
pandem
influenza
vaccin
could
theori
support
vaccin
popul
two
dose
vaccin
howev
global
distribut
vaccin
product
far
equal
industri
nation
develop
world
accord
survey
made
influenza
vaccin
dose
distribut
among
southeast
asia
eastern
mediterranean
africa
region
compris
half
world
popul
addit
current
licens
vaccin
would
take
month
identif
pandem
influenza
vaccin
distribut
would
give
pandem
viru
ampl
time
global
spread
henc
technolog
enabl
fast
product
larg
amount
vaccin
dire
need
face
pandem
threat
effort
meet
challeng
made
monitor
virus
high
pandem
potenti
program
notabl
coalit
epidem
prepared
innov
cepi
financ
develop
vaccin
like
pandem
threat
wide
array
differ
virus
employ
basi
construct
viral
vector
base
vaccin
among
other
vector
includ
adenovirus
parvovirus
eg
adenoassoci
virus
aav
togavirus
eg
semliki
forest
viru
paramyxovirus
eg
measl
viru
newcastl
diseas
viru
human
parainfluenza
viru
rhabdovirus
eg
vesicular
stomat
viru
vsv
poxvirus
eg
modifi
vaccinia
ankara
mva
sinc
comprehens
discuss
vector
would
exceed
scope
review
describ
commonli
use
viral
vector
ie
adenoviru
measl
viru
vsv
detail
whose
use
clinic
studi
discuss
adenoviru
ad
vector
among
commonli
employ
viral
vector
vast
amount
preclin
clinic
studi
assess
protect
efficaci
varieti
infecti
diseas
avail
adenovirida
nonenvelop
virus
icosahedr
capsid
linear
doublestrand
dna
genom
whose
size
rang
kb
next
multitud
adenovirus
occur
differ
anim
speci
identifi
human
adenoviru
classifi
seven
speci
adenovir
receptor
express
surfac
human
cell
allow
broad
tissu
tropism
viru
ad
base
vaccin
construct
replicationcompet
replicationdefect
vector
gener
replac
earli
transcript
b
genom
region
antigen
express
cassett
therebi
abolish
viral
abil
replic
addit
viral
gene
frequent
delet
prevent
elimin
ad
infect
cell
immun
system
leaki
express
insert
antigen
respect
sinc
adenovirus
shuttl
genom
nucleu
host
cell
transcript
replic
risk
genom
integr
exist
howev
vector
predominantli
remain
episom
adenovir
vector
abl
stabli
express
insert
kb
support
express
target
antigen
well
multival
multipathogen
vaccin
vector
easili
manipul
insert
transgen
cassett
viral
backbon
via
homolog
recombin
direct
clone
step
vitro
adenovir
vector
manufactur
mammalian
cell
cultur
system
commonli
use
hek
cell
provid
protein
tran
allow
viral
replic
product
system
support
high
viral
yield
rel
low
product
cost
amplif
viral
seed
requir
biosafeti
level
facil
adenovir
vector
abl
induc
potent
antibodi
well
cell
respons
variat
immun
respons
depend
serotyp
employ
replicationdefici
one
wide
use
adenovir
vector
abl
induc
except
potent
cell
well
antibodi
respons
howev
widespread
preexist
immun
viru
human
popul
inhibit
transgen
express
inactiv
viral
vector
hamper
clinic
use
issu
met
develop
adenovir
vector
nonhuman
origin
chimpanze
viru
deriv
vector
altern
approach
select
rare
serotyp
low
preval
human
induc
enhanc
memori
polyfunct
cell
compar
measl
viru
mv
common
human
pathogen
belong
famili
paramyxovirida
mv
envelop
viru
nonseg
negativesens
singlestrand
rna
genom
kb
measl
viru
vaccin
gener
serial
passag
infecti
viru
differ
cell
line
result
live
attenu
viru
replic
defici
human
introduct
numer
mutat
process
establish
highli
stabl
vaccin
revers
pathogen
never
observ
moreov
mv
unabl
integr
host
genom
lyophil
process
mv
vaccin
establish
increas
thermost
natur
unstabl
viru
mv
vaccin
induc
extrem
durabl
respons
antibodi
cell
persist
long
year
post
vaccin
due
helic
natur
ribonucleoprotein
rnp
complex
viral
genom
highli
flexibl
accept
insert
kb
long
total
number
nucleotid
genom
divid
rule
six
abil
accept
rel
larg
transgen
offer
opportun
gener
multipathogen
multival
vaccin
howev
need
rescu
negativesens
rna
genom
revers
genet
render
manufactur
viru
insert
transgen
complex
compar
viral
vector
sever
way
gener
transgen
express
mv
describ
transgen
cassett
insert
differ
posit
viral
genom
mv
vaccin
grown
chick
embryon
fibroblast
cell
line
vero
cell
manufactur
process
clinic
use
wellestablish
howev
manufactur
bulk
vaccin
product
requir
facil
might
restrict
avail
manufactur
facil
outbreak
set
recombin
measl
virus
abl
induc
high
level
humor
cellular
immun
respons
transgen
importantli
mv
abl
infect
cell
immun
system
includ
macrophag
dendrit
cell
thu
support
deliveri
target
antigen
directli
antigenpres
cell
cellmedi
respons
mv
domin
phenotyp
unlik
domin
respons
adenovir
vector
might
consider
vaccin
develop
sinc
live
attenu
mv
routin
use
vaccin
child
immun
program
mani
countri
preexist
immun
mv
viral
vector
rais
concern
howev
studi
mice
macaqu
show
impact
previou
mv
exposur
transgen
immun
agreement
anim
studi
clinic
studi
conduct
context
mv
vaccin
chikv
likewis
demonstr
antivector
immun
compromis
vaccin
efficaci
vesicular
stomat
viru
vsv
member
rhabdovirida
famili
envelop
viru
contain
singl
strand
negativesens
rna
kb
viru
natur
infect
livestock
sporad
infect
found
human
result
low
risk
preexist
immun
lack
dna
intermedi
viral
replic
make
vsv
attract
safe
vaccin
applic
human
establish
revers
genet
system
vsv
allow
manipul
propag
viru
vsv
gener
employ
attenu
vector
achiev
differ
method
introduc
mutat
viral
matrix
protein
rearrang
order
viral
protein
insert
nonvir
protein
partial
complet
delet
viral
glycoprotein
g
determin
viral
infect
attenu
essenti
vaccin
safeti
sinc
neurovirul
wildtyp
vsv
detect
upon
intracrani
inocul
anim
model
transgen
insert
differ
posit
viral
genom
result
vari
level
transgen
express
common
method
transgen
insert
replac
g
protein
alter
tissu
tropism
viru
amount
addit
genom
materi
stabli
accept
genom
kb
vsv
grown
high
titer
mammalian
insect
cell
line
depend
way
viru
manipul
method
viral
propag
may
vari
vsv
induc
robust
antigenspecif
neutral
antibodi
respons
modest
cell
immun
describ
sever
studi
howev
asset
vaccin
effect
induct
humor
respons
administr
viralvector
take
place
differ
rout
next
intramuscular
vaccin
intranas
intraderm
oral
vaccin
test
differ
virus
clinic
studi
next
abil
employ
viru
infect
certain
tissu
choic
immun
rout
depend
sever
consider
rout
administr
affect
qualiti
induc
immun
respons
choic
applic
rout
thu
depend
target
pathogen
ie
mucos
respons
requir
induc
protect
oral
nasal
deliveri
vaccin
may
prefer
parenter
applic
addit
rout
administr
need
reliabl
easi
perform
outbreak
situat
argu
establish
rout
vaccin
oral
intramuscular
administr
sinc
viralvector
complex
vaccin
induc
strong
immun
respons
use
addit
adjuv
gener
requir
clinic
studi
test
recombin
viral
vaccin
combin
addit
immunestimul
compon
found
increas
immun
adjuv
group
nevertheless
modif
immunolog
compart
introduc
adjuv
might
still
prove
benefici
context
viral
vector
given
larg
amount
differ
viral
vector
avail
vast
knowledg
gather
manipul
function
immunogen
viral
vector
base
vaccin
repres
valuabl
highli
versatil
platform
vaccin
develop
viral
genom
manipul
express
antigen
choic
abil
stabli
accept
rel
larg
insert
genom
support
develop
larg
varieti
vaccin
deliveri
target
antigen
genet
inform
allow
faith
antigen
gener
target
process
ie
correct
protein
fold
multimer
modif
glycosyl
specif
target
cell
ensur
note
mostli
hold
true
viral
target
antigen
deriv
human
pathogen
express
natur
environ
wherea
isol
bacteri
parasit
antigen
might
local
process
differ
mammalian
cell
compar
natur
host
viral
vector
induc
stimuli
target
cell
mimic
natur
infect
therebi
induc
potent
immun
respons
henc
viral
vector
base
vaccin
deliv
without
addit
adjuv
variat
depend
vector
employ
see
strong
antigenspecif
cellular
humor
immun
respons
target
antigen
induc
strategi
achiev
replic
incompet
attenu
modern
viral
vector
gener
ensur
good
safeti
profil
viral
vector
base
vaccin
commonli
employ
viral
vector
base
vaccin
high
yield
product
process
mean
upscal
establish
support
use
technolog
pandem
set
despit
mani
advantag
sever
aspect
consid
develop
viral
vector
base
vaccin
firstli
viral
vector
genet
modifi
organ
gmo
therefor
consid
potenti
risk
human
health
environ
associ
releas
organ
european
regulatori
agenc
requir
environment
risk
assess
era
evalu
potenti
environment
health
risk
pose
gmo
usa
fda
publish
guidelin
environment
assess
ea
use
viral
vector
base
vaccin
rais
safeti
concern
use
human
potenti
integr
host
genom
high
persist
replic
attenu
vaccin
need
care
assess
entri
well
clinic
develop
concern
import
term
safeti
might
also
lead
delay
clinic
studi
case
pandem
term
vaccin
manufactur
viral
system
requir
differ
cellular
system
high
yield
propag
necessit
differ
manufactur
facil
viral
vector
platform
virus
may
undergo
recombin
product
great
care
must
taken
keep
cell
cultur
free
materi
lead
emerg
recombin
uncharacter
pathogen
gener
presenc
adventiti
agent
ie
microorgan
may
unintent
introduc
manufactur
process
need
assess
vigor
vaccin
manufactur
sinc
product
viral
vector
base
vaccin
complex
process
often
requir
multitud
compon
human
anim
origin
cell
substrat
porcin
trypsin
bovin
serum
need
exclud
contamin
requir
extens
test
variou
step
manufactur
process
inde
sever
exampl
contamin
viral
vaccin
porcin
circoviru
contamin
rotaviru
vaccin
highlight
realiti
risk
factor
make
product
viral
vector
base
vaccin
highli
complex
compar
costintens
process
viral
vector
deriv
viru
abl
infect
human
effect
preexist
immun
vector
immunogen
address
depend
vector
effect
may
may
hamper
immun
respons
case
mv
vector
respect
see
dampen
immun
respons
preexist
immun
may
necessit
time
cost
intens
screen
procedur
clinic
trial
compromis
use
given
vector
indic
vaccine
viral
vector
base
vaccin
employ
develop
vaccin
mani
differ
pathogen
vast
number
preclin
clinic
studi
howev
far
one
viral
vector
base
vaccin
ie
dengvaxia
recombin
dengu
vaccin
base
yellow
fever
attenu
strain
licens
human
use
comprehens
summari
applic
context
prophylact
vaccin
publish
elsewher
review
focu
two
exemplari
vector
base
vaccin
develop
context
recent
ebola
pandem
order
highlight
advantag
disadvantag
technolog
outbreak
situat
first
studi
employ
viral
vector
base
approach
develop
vaccin
ebolavirus
start
earli
howev
approach
still
preclin
stage
ebola
pandem
emerg
viral
vector
base
vaccin
ebolavirus
test
context
nonrepl
vector
modifi
vaccinia
strain
ankara
mva
human
adenoviru
ad
replicationdefect
recombin
chimpanze
adenoviru
vaccin
well
replic
compet
vector
includ
vsvebov
human
parainfluenza
viru
type
recombin
cytomegaloviru
rcmv
recombin
rabi
viru
rabv
clinic
trial
conduct
vsvebov
vaccin
mvavector
vaccin
vaccin
reli
vector
base
express
viral
glycprotein
gp
surfac
protein
singl
target
neutral
antibodi
alon
combin
addit
viral
protein
focu
discuss
two
adenovirus
ie
vsvebov
vector
three
earliest
vector
base
vaccin
enter
clinic
trial
upon
pandem
first
adenoviru
base
vaccin
ebola
replic
defect
express
ebov
gp
describ
test
combin
dna
vector
vaccin
nonhuman
primat
nhp
vaccin
found
protect
requir
long
vaccin
schedul
vaccin
develop
gener
vector
express
gp
nucleoprotein
np
enhanc
cell
respons
inde
vaccin
vector
result
complet
protect
nhp
upon
singl
vaccin
protect
found
correl
gener
specif
cell
antibodi
respons
studi
employ
vector
develop
crucel
holland
bv
express
gp
two
ebolaviru
subspeci
ebola
viru
ebov
sudan
ebolaviru
sudv
featur
point
mutat
reduc
protein
cytotox
vaccin
found
protect
nhp
allow
delet
np
construct
well
dose
spare
given
encourag
result
clinic
trial
initi
tabl
studi
show
safeti
well
induct
antibodi
cell
respons
signific
gener
viru
neutral
titer
importantli
studi
also
demonstr
induct
antibodi
reduc
particip
preexist
immun
given
high
preval
human
popul
find
might
compromis
use
develop
human
vaccin
upon
outbreak
ebola
pandem
new
base
vaccin
develop
joint
effort
beij
institut
biotechnolog
tianjin
cansino
biotechnolog
inc
vaccin
first
incorpor
gp
epidem
ebola
strain
produc
lyophil
powder
facilit
vaccin
transport
storag
allow
storag
phase
clinic
trial
initi
end
show
seriou
advers
event
although
higher
incid
injectionsit
reaction
associ
higher
dose
tabl
importantli
studi
show
high
dose
vector
abl
overcom
neg
effect
preexist
immun
particip
high
baselin
concentr
neutral
antibodi
still
induc
robust
gpspecif
antibodi
cell
respons
phase
ii
clinic
studi
test
viral
vector
initi
sierra
leon
octob
tabl
result
yet
publicli
avail
addit
vector
base
strategi
limit
associ
high
preval
viru
human
popul
met
parallel
approach
employ
far
less
preval
relat
virus
chimpanze
deriv
adenovirus
especi
among
wide
evalu
vector
develop
vaccin
ebola
two
vaccin
develop
niaid
vrc
ie
replic
defect
encod
ebov
gp
alon
combin
sudv
gp
test
preclin
studi
demonstr
complet
protect
nhp
vaccin
week
singl
inject
use
viral
particl
howev
immun
respons
wane
sever
month
prime
vaccin
could
prevent
boost
mva
encod
gp
ebov
sudv
start
septemb
vaccin
test
phase
clinic
trial
demonstr
accept
safeti
profil
vector
induct
gp
specif
antibodi
respons
almost
subject
well
cell
respons
subset
studi
particip
tabl
encod
ebov
gp
move
phase
ii
clinic
studi
licens
gsk
publish
result
phase
iii
clinic
trial
report
immunogen
almost
vaccin
recipi
significantli
increas
antibodi
respons
vaccin
group
compar
placebo
group
month
tabl
importantli
prevail
studi
phase
ii
clinic
trial
directli
compar
rvsvzebov
base
vaccin
demonstr
vaccin
elicit
immun
respons
one
month
vaccin
larg
maintain
month
addit
trial
evalu
primeboost
regimen
follow
mva
vaccin
overal
base
vaccin
appear
safe
efficaci
candid
ebola
vaccin
develop
rvsvzebov
current
repres
promis
candid
develop
effect
vaccin
ebolavirus
vaccin
consist
live
attenu
vsv
vsv
glycoprotein
remov
replac
gp
ebov
strain
rvsvzebov
develop
canadian
nation
microbiolog
laboratori
licens
merck
preclin
studi
publish
respect
demonstr
complet
protect
lethal
ebov
challeng
infect
mice
use
mouseadapt
strain
nhp
singl
inject
rvsvzebov
demonstr
fulli
protect
nph
vaccin
appli
seven
day
challeng
show
promis
postexposur
prophylaxi
nhp
inject
one
two
dose
vaccin
h
ebov
exposur
result
protect
vaccin
test
ten
complet
phase
clinic
trial
earliest
studi
initi
octob
first
result
clinic
studi
publish
show
robust
persist
induct
gp
specif
antibodi
respons
well
viru
neutral
titer
higher
titer
elicit
higher
dose
group
tabl
howev
studi
also
rais
safeti
concern
dose
pfu
higher
associ
develop
arthriti
last
median
day
addit
particip
experienc
arthralgia
develop
maculopapular
rash
indic
vsv
replic
dissemin
follow
studi
suspend
resum
one
month
later
use
lower
dose
pfu
reduct
viral
titer
employ
vaccin
yield
reduc
advers
event
howev
frequenc
gp
specif
antibodi
induct
remain
similar
cohort
vaccin
higher
dose
level
antibodi
respons
reduc
note
phase
clinic
trial
tabl
employ
high
dose
rvsvzebov
demonstr
dosedepend
induct
gp
reactiv
antibodi
titer
particip
mild
advers
event
without
case
arthriti
phase
iiiii
clinic
trial
initi
guinea
march
assess
vaccin
efficaci
upon
vaccin
use
one
dose
pfu
cluster
random
design
ring
vaccin
approach
tabl
particip
includ
individu
high
risk
assign
cluster
randomli
subject
immedi
delay
vaccin
day
later
studi
report
demonstr
promis
result
case
ebola
viru
diseas
symptom
onset
least
day
random
detect
immedi
vaccin
group
case
ebola
viru
diseas
seven
cluster
occur
delay
vaccin
group
demonstr
vaccin
efficaci
seriou
event
regist
upon
vaccin
one
judg
causal
relat
vaccin
given
result
rvsv
zebov
current
promis
candid
licens
vaccin
ebola
viru
dna
vaccin
gener
insert
eukaryot
express
cassett
encod
antigen
choic
bacteriaderiv
plasmid
plasmid
backbon
gener
contain
element
permit
propag
select
vector
escherichia
coli
ie
origin
replic
support
high
yield
plasmid
bacteri
growth
select
marker
mostli
bacteri
antibiot
resist
gene
kanamycin
allow
stabl
inherit
vector
sinc
regulatori
safeti
concern
rais
presenc
nonfunct
sequenc
especi
antibiot
resist
marker
human
use
marker
replac
remov
new
gener
dna
vaccin
addit
minim
dna
construct
devoid
bacteri
backbon
semisynthet
minicircl
dna
fulli
synthet
develop
eukaryot
express
cassett
compris
promotor
typic
deriv
cytomegaloviru
cmv
support
high
transcript
level
gene
interest
polyadenyl
poli
signal
requir
nuclear
export
translat
stabil
transcript
mrna
usual
obtain
rabbit
bovin
growth
hormon
gene
research
dna
vaccin
start
earli
common
rout
administr
intramuscular
im
intraderm
id
inject
use
convent
needl
howev
vaccin
dna
vector
alon
gener
lead
rel
low
immunogen
especi
larg
anim
model
human
factor
may
play
role
need
dna
vaccin
cross
two
cellular
membran
ie
plasma
well
nuclear
membran
order
achiev
protein
express
note
hold
true
rna
vaccin
translat
upon
cross
plasma
endosom
membran
respect
henc
addit
method
develop
abl
enhanc
dna
uptak
express
immunogen
includ
variou
deliveri
devic
gene
gun
needl
free
inject
devic
jet
inject
vivo
electropor
among
wide
use
shown
yield
promis
result
preclin
clinic
trial
furthermor
differ
formul
dna
test
ie
encapsul
lipid
nanoparticl
contain
cation
lipid
cholesterol
adsorpt
polym
polyethyleneimin
adsorpt
encapsul
biodegrad
nanoparticl
poli
lacticcoglycol
acid
plga
chitosan
method
larg
direct
improv
uptak
dna
molecul
cell
thu
enhanc
antigen
express
addit
differ
approach
modifi
improv
dna
mediat
immun
respons
develop
molecular
adjuv
pattern
recognit
receptor
prr
ligand
differ
cytokin
commonli
codeliv
encod
antigen
strategi
direct
antigen
certain
cellular
compart
specif
target
antigen
present
cell
apc
enhanc
immun
respons
establish
addit
dna
vaccin
success
employ
primeboost
regimen
combin
vaccin
technolog
protein
viral
vector
base
vaccin
although
multitud
studi
show
dna
vaccin
abl
elicit
humor
cellular
immun
respons
activ
cytotox
helper
cell
respect
exact
mechan
action
remain
evalu
upon
entri
cell
dna
vaccin
sens
varieti
innat
immun
receptor
critic
dna
vaccin
efficaci
pathway
inflammasom
involv
dna
vaccin
mode
action
factor
might
addit
involv
earli
experi
test
bombard
dna
coat
gold
particl
deliv
id
demonstr
transfect
keratinocyt
profession
apc
ie
langerhan
cell
explain
sourc
mhci
mhcii
restrict
antigen
recognit
cytotox
helper
cell
respect
howev
im
vaccin
dna
vector
mostli
result
transfect
myocyt
sinc
sever
studi
establish
role
bone
marrow
deriv
apc
activ
mhci
restrict
cell
upon
dna
vaccin
like
mechan
scenario
seem
crossprim
present
mhci
mhcii
restrict
antigen
profession
apc
upon
phagocytosi
transfect
somat
cell
specifi
use
nucleic
acid
base
vaccin
offer
number
advantag
differ
aspect
vaccin
develop
product
howev
employ
dna
basi
vaccin
also
implic
disadvantag
concern
context
longterm
persist
dna
plasmid
upon
inject
inde
dna
persist
shown
variou
preclin
studi
demonstr
presenc
plasmid
dna
year
upon
im
inject
low
detect
express
immunogen
mous
model
accord
fda
dna
persist
gener
evid
ectop
site
biodistribut
persist
studi
remain
detect
inject
site
period
exceed
especi
context
longterm
persist
presenc
foreign
genet
inform
nucleu
transfect
cell
pose
addit
risk
genom
integr
host
chromosom
result
threat
mutagenesi
oncogenesi
despit
neg
result
sever
studi
focus
detect
dna
integr
event
upon
im
inject
small
anim
model
genom
integr
event
detect
follow
electropor
mice
demonstr
integr
repres
small
risk
nevertheless
need
consid
system
enhanc
dna
uptak
fda
recommend
integr
studi
includ
whenev
plasmid
dna
exceed
copi
per
host
dna
persist
tissu
studi
termin
advis
integr
studi
part
preclin
safeti
program
dna
addit
inject
bacteri
dna
sens
presenc
unmethyl
cpg
motif
associ
safeti
concern
gener
antibodi
inject
dna
howev
antidna
antibodi
detect
mice
rat
rabbit
nonhuman
primat
potenti
express
antibiot
resist
marker
vaccin
organ
likewis
rais
safeti
concern
met
replac
marker
next
gener
dna
vaccin
lastli
express
cytokin
costimulatori
molecul
use
enhanc
dna
immunogen
might
lead
unintend
advers
effect
upon
cytokin
express
releas
gener
immun
suppress
chronic
inflamm
autoimmun
recommend
monitor
persist
cytokin
express
plasmid
well
appropri
preclin
model
anim
model
respons
respect
human
cytokin
ensur
vaccin
safeti
sinc
first
experi
dna
vaccin
employ
vaccin
develop
clinic
trial
larg
varieti
human
pathogen
hiv
influenza
viru
malaria
hepat
b
viru
respiratori
syncyti
herp
simplex
viru
dna
base
vaccin
licens
human
use
yet
sever
dna
base
vaccin
licens
veterinari
applic
equin
vaccin
west
nile
viru
given
high
degre
versatil
dna
vaccin
test
efficaci
protect
recent
pandem
threat
includ
hiv
mer
ebola
zika
discuss
detail
first
effect
vaccin
ebolavirus
develop
preclin
experi
employ
dna
vector
base
antigen
express
approach
reli
express
viral
glycoprotein
gp
induc
neutral
antibodi
well
nucleoprotein
np
target
antibodi
well
cell
respons
induct
humor
cellmedi
immun
well
protect
efficaci
rodent
adapt
viral
strain
demonstr
guinea
pig
mice
upon
vaccin
dna
encod
gp
np
use
intramuscular
inject
intraderm
deliveri
use
gene
gun
respect
later
studi
establish
protect
induc
trival
dna
vaccin
encod
gp
two
ebolavirus
marburgviru
protect
lethal
challeng
ebolaviru
ebola
viru
ebov
upon
dna
vaccin
combin
adenovir
vector
nonhuman
primat
set
promis
preclin
data
establish
first
phase
clinic
trial
use
dna
vaccin
ebola
start
well
ebola
crisi
tabl
studi
employ
trival
dna
vaccin
consist
plasmid
encod
transmembranedelet
form
gp
deriv
two
ebolavirus
well
np
produc
vical
inc
result
demonstr
safeti
toler
vaccin
well
specif
antibodi
respons
least
one
three
antigen
subject
howev
detect
viru
neutral
respons
elicit
trial
phase
clinic
trial
conduct
employ
wildtyp
gp
construct
found
elicit
superior
respons
transmembran
delet
gp
context
adenovir
deliveri
nhp
tabl
two
differ
dna
vaccin
encod
gp
two
speci
ebolaviru
produc
vrcniaid
vaccin
pilot
plant
oper
leido
marburg
marburgviru
marv
gp
produc
althea
technolog
respect
administ
studi
confirm
safeti
dna
vaccin
subject
found
elicit
specif
antibodi
respons
one
gp
given
reassur
safeti
profil
phase
ib
studi
conduct
uganda
tabl
vaccin
well
toler
immun
respons
remain
poor
around
subject
elicit
antibodi
respons
ebolaviru
marv
compon
respect
overal
result
earli
gener
dna
base
vaccin
somewhat
discourag
howev
effort
renew
use
improv
dna
technolog
upon
outbreak
inovio
develop
test
gp
encod
dna
vaccin
candid
combin
two
dna
vaccin
ie
encod
gp
deriv
current
viral
isol
respect
prove
versatil
speed
approach
clinic
trial
initi
earli
tabl
studi
assess
vaccin
safeti
toler
immunogen
compon
without
encod
plasmid
preliminari
result
shown
favor
safeti
profil
particip
gener
ebolaspecif
antibodi
immun
respons
larg
number
preclin
clinic
studi
assess
abil
dna
vaccin
mediat
protect
influenza
virus
either
alon
part
prime
boost
strategi
vaccin
mainli
reli
plasmid
base
express
hemagglutinin
ha
one
viral
surfac
antigen
main
target
neutral
antibodi
influenza
term
pandem
prepared
dna
vaccin
strategi
vical
inc
develop
test
vaccin
target
highli
pathogen
avian
influenza
endem
poultri
abil
cross
speci
barrier
first
discov
caus
rise
number
human
infect
render
viru
high
pathogen
risk
far
viru
abl
spread
effici
sustain
human
human
bird
human
infect
caus
death
peopl
worldwid
dna
vaccin
express
ha
viral
strain
either
employ
alon
combin
conserv
nucleoprotein
np
ion
channel
protein
deriv
differ
subtyp
target
cell
respons
np
previous
shown
protect
mice
lethal
challeng
absenc
ha
compon
clinic
trial
test
dna
vaccin
combin
lipidbas
adjuv
initi
protect
efficaci
demonstr
preclin
studi
mice
ferret
tabl
vaccin
found
well
toler
hi
titer
correl
protect
elicit
maximum
ha
trival
group
respect
upon
emerg
novel
influenza
origin
pig
becam
pandem
human
spring
effort
made
acceler
develop
vaccin
clinic
trial
initi
august
use
dna
base
approach
encod
hemagglutinin
protein
whose
gmp
product
final
month
licens
monoval
influenza
vaccin
becam
avail
tabl
howev
week
last
vaccin
subject
develop
posit
hi
respons
increas
week
boost
licens
monoval
influenza
vaccin
base
result
gain
point
abil
fast
manufactur
larg
number
dose
could
support
use
dnabas
vaccin
control
potenti
influenza
pandem
employ
dna
initi
prime
agent
follow
boost
convent
influenza
vaccin
upon
avail
dna
base
vaccin
among
first
proceed
clinic
trial
upon
zika
crisi
leverag
knowledg
gener
context
flavivirus
approach
reli
express
precursor
membran
envelop
env
prme
protein
known
form
subvir
particl
env
target
viru
neutral
antibodi
first
approach
develop
inovio
employ
consensu
prme
deriv
african
recent
asian
american
strain
modifi
contain
ige
signal
peptid
put
glycosyl
site
remov
vaccin
shown
immunogen
protect
mous
model
upon
im
vaccin
follow
electropor
passiv
transfer
experi
vaccineinduc
sera
interferon
ifn
receptor
knockout
mice
demonstr
correl
antibodi
level
protect
furthermor
induct
viru
antibodi
cell
respons
upon
id
vaccin
follow
electropor
shown
nhp
base
result
two
phase
clinic
studi
initi
one
flavivirusna
individu
start
juli
one
dengu
viru
seroposit
subject
began
august
tabl
preliminari
result
demonstr
vaccin
welltoler
induc
neutral
antibodi
particip
preclin
studi
publish
octob
demonstr
induct
neutral
antibodi
protect
challeng
infect
nhp
upon
two
im
vaccin
use
needl
free
inject
devic
studi
employ
two
differ
prme
construct
base
sequenc
french
polynesian
earli
brazilian
zikv
isol
zika
prm
signal
sequenc
alon
combin
stem
transmembran
region
exchang
correspond
sequenc
japanes
enceph
viru
jev
vaccin
candid
evalu
clinic
studi
vaccin
research
center
vrc
nation
institut
allergi
infecti
diseas
niaid
tabl
clinic
trial
test
nct
initi
august
decemb
respect
result
phase
studi
publish
lancet
decemb
trial
show
vaccin
safe
well
toler
induc
humor
cell
respons
posit
neutral
antibodi
respons
rang
detect
week
final
vaccin
agreement
preclin
studi
yield
better
respons
dna
base
approach
develop
effect
zika
vaccin
appear
safe
human
use
yield
promis
result
importantli
initi
within
month
sequenc
becam
avail
highlight
versatil
speed
provid
dna
vaccin
platform
mrna
intermedi
carrier
genet
inform
use
templat
endogen
protein
product
vaccin
subject
two
major
type
rna
util
prophylact
vaccin
pathogen
caus
infecti
diseas
nonrepl
mrnaselfamplifi
mrna
nonrepl
mrna
contain
sequenc
antigen
choic
flank
untransl
region
utr
advantag
use
nonrepl
mrna
vaccin
compar
selfamplifi
mrna
root
simplic
construct
small
size
rna
absenc
addit
encod
protein
could
induc
unintend
immun
respons
design
optim
effici
translat
mrna
use
vaccin
review
previous
briefli
convent
nonrepl
mrna
obtain
vitro
transcript
cdna
templat
typic
plasmid
dna
pdna
produc
e
coli
pdna
templat
linear
use
restrict
enzym
transcrib
vitro
mrna
mixtur
contain
recombin
phage
dnadepend
rna
polymeras
typic
deriv
phage
nucleosid
triphosph
ntp
upon
purif
usual
via
fplc
hplc
remov
remain
product
relat
impur
reaction
compon
ie
enzym
free
ntp
residu
pdna
abort
transcript
byproduct
pure
singl
mrna
product
obtain
notabl
purif
vitro
transcrib
mrna
seem
crucial
amount
immunogen
produc
target
cell
demonstr
increas
protein
product
primari
human
dc
transfect
hplc
purifi
compar
unpurifi
mrna
vitro
transcrib
mrna
product
contain
proteinencod
open
read
frame
orf
flank
element
essenti
function
matur
eukaryot
mrna
cap
structur
join
poli
tail
end
well
untransl
region
utr
cap
vital
creation
stabl
matur
mrna
increas
protein
translat
via
bind
eukaryot
translat
initi
factor
cap
ad
either
transcript
inclus
cap
analog
antirevers
cap
arca
reaction
subsequ
use
vaccinia
viru
cap
complex
utr
eukaryot
viral
origin
increas
halflif
stabil
mrna
result
higher
express
protein
poli
tail
optim
length
essenti
regulatori
element
enhanc
translat
either
encod
dna
templat
altern
ad
enzymat
post
transcript
sequenc
orf
optim
use
either
enrich
gc
content
replac
rare
codon
frequent
use
synonym
codon
lead
increas
protein
product
mrna
util
chemic
modifi
nucleosid
decreas
innat
immun
activ
increas
translat
mrna
selfampifi
mrna
vaccin
commonli
base
alphaviru
genom
review
detail
gene
encod
structur
protein
replac
antigen
choic
despit
gene
delet
viral
rna
replic
transcrib
viral
rna
polymeras
full
length
mrna
selfamplifi
mrna
vaccin
substanti
larger
kb
alphaviru
system
nonrepl
mrna
vaccin
contain
essenti
element
cap
utr
poli
tail
note
lower
yield
increas
occurr
abort
construct
consequ
larg
size
vaccin
pose
challeng
vaccin
product
make
manufactur
process
difficult
compar
nonrepl
mrna
vaccin
addit
mrna
contain
subgenom
promot
larg
orf
encod
nonstructur
protein
follow
deliveri
vaccin
cytosol
transcrib
four
function
compon
encod
rnadepend
rna
polymeras
rdrp
rdrp
produc
negativesens
copi
genom
serv
templat
two
positivestrand
rna
molecul
genom
mrna
shorter
subgenom
mrna
subgenom
mrna
transcrib
high
level
allow
amplif
mrna
encod
antigen
choic
henc
genet
inform
encod
selfamplifi
mrna
vaccin
amplifi
mani
time
result
high
level
antigen
express
rel
low
dose
vaccin
appeal
attribut
selfamplifi
mrna
vaccin
compar
nonrepl
mrna
vaccin
upon
inject
mice
lnpformul
selfamplifi
mrna
encod
firefli
luciferas
induc
protein
express
last
almost
two
month
upon
im
deliveri
luciferas
express
protamineformul
nonrepl
mrna
administ
id
usual
detect
sever
day
howev
potenti
interact
host
encod
alphavir
nonstructur
protein
necessit
investig
selfamplifi
mrna
commonli
deliv
synthet
deliveri
vehicl
discuss
altern
method
packag
deliveri
viruslik
replicon
particl
vrp
produc
helper
cell
line
provid
capsid
glycoprotein
gene
tran
lack
structur
protein
gene
contain
vrp
prevent
product
viral
particl
celltocel
spread
vrp
capabl
infect
cell
express
antigen
choic
vitro
vivo
although
preclin
clinic
data
vrp
promis
technolog
requir
use
electropor
genet
materi
cell
cultur
cell
manufactur
process
although
electropor
success
employ
gmp
condit
scale
suffici
provid
materi
phase
studi
costeffect
product
industri
scale
may
challeng
addit
safeti
concern
associ
vrp
sinc
recombin
copackag
replicon
helper
rna
vrp
product
cell
contain
replicon
helper
rna
could
lead
gener
infecti
virus
order
act
vaccin
exogen
mrna
enter
cytoplasm
protein
express
take
place
step
plasma
endosom
lipid
membran
repres
barrier
mrna
vaccin
cross
effici
possibl
addit
induct
effect
immun
respons
requir
stimul
innat
immun
system
mrna
vaccin
mrna
intrins
innat
stimul
function
see
effect
increas
differ
way
mrna
formul
henc
sever
method
increas
cell
deliveri
adjuvant
mrna
vaccin
develop
immun
take
place
via
direct
inject
nake
mrna
especi
via
rout
lead
effect
target
apc
intraderm
intranod
administr
howev
deliv
im
humor
cellular
immun
respons
induc
nake
mrna
remain
low
compar
lnpformul
mrna
physic
deliveri
method
mrna
vaccin
like
increas
vaccin
releas
cytoplasm
shown
induc
immun
respons
mice
upon
administr
nonrepl
mrna
selfamplifi
mrna
use
gene
gun
vivo
electropor
respect
commonli
use
strategi
increas
express
immunogen
deliveri
mrna
complex
addit
compon
among
first
approach
format
whose
two
compon
free
protaminecomplex
mrna
small
argininerich
nuclear
protein
stabil
nucleic
acid
provid
strong
antigen
express
immunostimul
vaccin
format
prove
immunogen
capabl
induct
protect
lethal
challeng
infect
influenza
rabi
viru
sever
anim
model
use
format
candid
vaccin
rabi
investig
first
ever
prophylact
mrnabas
vaccin
healthi
human
volunt
subject
receiv
mrna
vaccin
three
time
convent
needlebas
inject
needlefre
inject
devic
via
intraderm
id
intramuscular
im
rout
vaccin
gener
safe
reason
toler
profil
led
induct
neutral
antibodi
titer
level
iuml
higher
correl
protect
subject
receiv
id
inject
mrna
vaccin
needlefre
intraderm
inject
needlebas
inject
ineffect
antibodi
respons
wane
one
year
first
vaccin
could
boost
iuml
higher
subject
use
mrna
deliv
id
needl
free
inject
devic
indic
induct
b
cell
memori
respons
although
mrna
vaccin
candid
abl
induc
antibodi
respons
improv
increas
magnitud
longev
immun
respons
imper
develop
effect
vaccin
efficaci
mrna
vaccin
benefit
significantli
complex
agent
lipid
polymerbas
nanoparticl
enhanc
uptak
cell
improv
deliveri
translat
machineri
cytoplasm
although
commerci
avail
cation
lipid
polym
eg
transitmrna
micru
bio
llc
lipofectamin
invitrogen
effici
transfect
reagent
mrna
cell
line
primari
cell
use
vivo
mrna
deliveri
limit
due
high
toxic
low
efficaci
transfect
safer
effect
complex
reagent
discuss
detail
recent
review
design
past
year
lead
expans
field
prophylact
use
develop
potent
versatil
mrna
vaccin
current
lipid
nanoparticl
lnp
promis
frequent
use
class
agent
vivo
deliveri
mrna
vaccin
lnp
intens
studi
context
sirna
well
toler
compar
nonvir
deliveri
system
lnp
reli
ioniz
amino
lipid
complex
neg
charg
mrna
support
assembl
nm
size
particl
promot
escap
mrna
endosom
compart
cytoplasm
mrna
translat
addit
ioniz
amino
lipid
phospholipid
cholesterol
lipidanchor
polyethylen
glycol
peg
commonli
use
compon
lnp
formul
cholesterol
act
stabil
element
play
import
role
transfect
cell
lipidanchor
peg
preferenti
deposit
lnp
surfac
act
barrier
steric
stabil
lnp
reduc
nonspecif
bind
protein
increas
halflif
lnp
furthermor
surfac
lnp
decor
specif
target
entiti
direct
vaccin
certain
tissu
cell
profession
apc
therebi
facilit
uptak
mrna
vaccin
desir
type
immun
cell
eventu
lead
enhanc
immun
respons
antigen
choic
sever
studi
demonstr
lnp
effect
agent
vivo
deliveri
nonrepl
selfamplifi
mrna
vaccin
addit
formul
rout
mrna
administr
crucial
impact
qualiti
strength
induc
immun
respons
lnpmrna
deliv
intraven
iv
primarili
target
liver
id
im
deliveri
gener
show
prolong
express
antigen
choic
inject
site
studi
compar
differ
rout
administr
lnpformul
mrna
code
luciferas
show
total
amount
protein
produc
largest
iv
administr
durat
luciferas
express
longest
id
follow
im
inject
intraderm
id
inject
deliv
mrna
vaccin
directli
skin
organ
dens
popul
profession
apc
langerhan
cell
epidermi
variou
dendrit
cell
dc
subtyp
dermi
id
rout
administr
shown
effect
induc
balanc
immun
respons
includ
antibodi
well
type
cytotox
cell
mrna
vaccin
formul
protamin
lnp
intramuscular
im
inject
vaccin
often
practic
rout
administr
human
sinc
rout
vaccin
simpl
carri
requir
much
train
implement
may
prefer
rout
administr
physician
carri
immun
region
affect
pandem
howev
need
educ
personnel
vaccin
peopl
might
repres
limit
factor
face
pandem
induct
strong
immun
respons
im
inject
mrna
repres
high
hurdl
due
lack
costimulatori
molecul
optim
antigen
present
muscl
cell
low
infiltr
muscl
tissu
immun
cell
thu
potent
im
mrna
vaccin
must
allow
high
antigen
express
present
simultan
induc
strong
immunostimulatori
signal
recruit
immun
cell
inject
site
im
administr
nonrepl
nucleosidemodifi
mrnalnp
vaccin
zika
viru
well
influenza
virus
prove
immunogen
provid
protect
preclin
studi
mice
ferret
nhp
singl
im
immun
nhp
lnpformul
mrna
encod
rabi
influenza
antigen
induc
protect
antibodi
titer
could
boost
remain
stabl
observ
period
one
year
exogen
mrna
immunostimulatori
recogn
varieti
cell
surfac
endosom
cytosol
innat
immun
receptor
mammalian
cell
sens
foreign
rna
via
prr
locat
endosom
rigi
pkr
locat
cytoplasm
well
activ
prr
mrna
vaccin
result
robust
innat
immun
respons
includ
product
chemokin
cytokin
tnf
inocul
site
innat
factor
crucial
induct
effect
adapt
immun
respons
encod
antigen
id
immun
mrna
vaccin
upregul
express
chemokin
includ
recruit
innat
immun
cell
dc
macrophag
site
inject
kowalczyk
et
al
show
skin
protamineformul
nonrepl
sequenc
optim
mrna
vaccin
taken
nonleukocyt
leukocyt
cell
latter
mostli
repres
apc
mrna
transport
drain
lymph
node
dln
migratori
dendrit
cell
moreov
encod
protein
express
effici
present
apc
within
dln
shown
cell
prolifer
immun
cell
activ
follow
induct
adapt
immun
importantli
immunostimul
limit
inject
site
lymphoid
organ
proinflammatori
cytokin
detect
serum
immun
mice
lazzaro
et
al
demonstr
tcell
prime
restrict
bonemarrowderiv
apc
may
involv
antigen
transfer
myocyt
suggest
crossprim
preval
mechan
upon
im
inject
selfamplifi
mrna
vaccin
mice
recent
public
lutz
et
al
provid
first
mechanist
insight
mode
action
lnpformul
nonrepl
sequenc
optim
mrna
vaccin
demonstr
strong
activ
innat
immun
respons
inject
site
dln
mice
im
inject
lnpformul
mrna
vaccin
result
spontan
uptak
mrna
cell
surround
inject
site
strong
express
insid
transient
transfect
cell
includ
resid
profession
apc
neutrophil
nonleukocyt
cell
interestingli
similar
observ
publish
use
lnpformul
nonrepl
mrna
vaccin
contain
modifi
nucleotid
induc
rapid
local
infiltr
neutrophil
monocyt
dc
site
administr
dln
inject
nhp
cell
effici
intern
lnp
mainli
monocyt
dc
translat
mrna
upregul
key
costimulatori
receptor
coincid
upregul
type
ifninduc
gene
includ
innat
immun
activ
transient
result
prime
antigenspecif
cell
exclus
vaccinedrain
ln
data
demonstr
mrnabas
vaccin
induc
typei
ifnpolar
innat
immun
combin
antigen
product
apc
lead
gener
potent
vaccinespecif
respons
profession
apc
dc
like
relev
cell
type
mrna
vaccin
play
critic
role
antigen
process
present
elicit
immun
respons
specif
antigen
transfect
dc
express
mrnaencod
antigen
nativ
form
express
protein
subsequ
process
antigen
peptid
present
mhc
class
mhc
class
ii
molecul
along
costimulatori
signal
cell
respect
antigen
express
correctli
fold
nativ
form
recogn
b
cell
respons
produc
antibodi
antigen
studi
nhp
investig
immunolog
event
lead
antibodi
respons
elicit
modifi
nonrepl
mrna
encod
influenza
ha
encapsul
lnp
show
id
im
administr
induc
titer
consid
protect
id
deliveri
gener
respons
rapidli
circul
influenza
memori
b
cell
expand
two
immun
along
transient
appear
plasmablast
memori
b
cell
pool
wane
time
remain
detect
throughout
studi
follow
immun
plasma
cell
pc
detect
bone
marrow
persist
throughout
week
observ
period
profound
declin
detect
im
group
compar
id
group
end
studi
germin
center
form
vaccinedrain
lymph
node
along
increas
circul
ico
follicular
helper
cell
popul
shown
correl
high
avid
antibodi
respons
season
influenza
vaccin
human
addit
nonrepl
sequenc
optim
mrna
vaccin
induc
longliv
function
antibodi
respons
ha
influenza
nhp
persist
one
year
result
indic
nonrepl
mrna
vaccin
potent
induc
immunolog
repertoir
associ
gener
high
magnitud
longliv
antibodi
although
inject
nake
mrna
via
id
intranod
rout
report
induc
immun
respons
mrna
alon
applic
broad
use
prophylact
vaccin
omnipres
extracellular
ribonucleas
catalyt
hydrolyz
rna
unprotect
nake
mrna
highli
unstabl
physiolog
condit
due
hydrophil
strong
net
neg
charg
rna
taken
effici
cell
applic
vivo
howev
challeng
overcom
complex
mrna
highli
effici
carrier
new
gener
lnp
describ
protect
mrna
ribonucleas
allow
prolong
vivo
express
antigen
choic
lead
gener
potent
humor
cellular
immun
respons
follow
vivo
administr
activ
innat
immun
respons
rna
vaccin
potenti
doubleedg
sword
system
type
ifn
produc
respons
activ
prr
facilit
adapt
immun
respons
lead
phosphoryl
eukaryot
translat
initi
factor
result
slowdown
eventu
inhibit
protein
translat
pepini
et
al
report
selfamplifi
mrna
vaccin
elicit
inflammatori
respons
within
hour
indic
upregul
sever
ifnstimul
gene
antigen
express
immunogen
enhanc
absenc
signal
suggest
reduct
earli
type
ifn
respons
could
improv
rna
vaccin
potenc
sever
approach
describ
aim
overcom
stall
translat
increas
degrad
mrna
induc
activ
type
interferon
pathway
one
approach
use
natur
occur
modifi
nucleotid
suppress
activ
innat
receptormedi
respons
kariko
other
found
compar
unmodifi
mrna
nucleosidemodifi
mrna
translat
effici
vitro
primari
dc
vivo
mice
second
approach
develop
curevac
ag
base
optim
nucleotid
sequenc
henc
codon
usag
reli
exclus
unmodifi
nucleotid
affect
mrna
stabil
immunogen
shown
thess
colleagu
sequenceoptim
unmodifi
mrna
led
higher
protein
express
vitro
hela
cell
vivo
mice
respect
mrna
contain
modifi
nucleosid
howev
remain
determin
approach
modifi
unmodifi
mrna
provid
better
basi
prophylact
vaccin
human
recent
human
clinic
studi
mild
moder
rare
case
sever
local
system
reaction
report
differ
mrna
platform
futur
studi
suitabl
anim
model
care
evalu
distribut
mrna
express
encod
antigen
distant
organ
potenti
safeti
risk
includ
local
system
effect
toxic
effect
new
deliveri
system
well
induct
selfreact
antibodi
human
mrna
vaccin
like
dna
vaccin
abl
induc
humor
cellular
immun
respons
encod
antigen
choic
allow
high
degre
adapt
term
manufactur
platform
allow
product
differ
vaccin
use
establish
product
process
facil
howev
sinc
product
process
mrna
base
vitro
system
requir
amplif
bacteria
cell
cultur
manufactur
mrna
vaccin
compar
short
simpl
monitor
process
mrna
vaccin
interact
hostcel
dna
avoid
potenti
risk
genom
integr
pose
dnabas
vaccin
sinc
mrna
vaccin
repres
minim
vector
contain
orf
encod
antigen
choic
flank
specif
regulatori
element
induc
antivector
immun
observ
certain
viral
vectorbas
platform
therefor
administ
multipl
time
furthermor
mrna
vaccin
administ
differ
rout
use
convent
needlebas
inject
unlik
dna
vaccin
requir
addit
administr
devic
gene
gun
electropor
therefor
mrna
vaccin
offer
flexibl
oneforal
largescal
rapid
costeffect
manufactur
process
fast
turnaround
time
vital
face
pandem
threat
requir
rapid
respons
platform
capabl
produc
protect
vaccin
short
timefram
necessari
protect
atrisk
popul
earli
impact
progress
outbreak
increas
number
preclin
studi
shown
promis
result
selfamplifi
nonrepl
mrna
vaccin
confer
protect
variou
pathogen
includ
pandem
potenti
selfamplifi
mrna
vaccin
encod
variou
influenza
antigen
complex
lnp
oilinwat
cation
nanoemuls
cne
immunogen
ferret
facilit
contain
viral
replic
upper
respiratori
tract
upon
influenza
infect
confer
protect
homolog
heterosubtyp
viral
challeng
mice
selfamplifi
mrna
vaccin
encod
clade
c
envelop
glycoprotein
formul
cne
induc
potent
cellular
well
bind
neutral
antibodi
respons
nhp
rna
replicon
encod
glycoprotein
complex
lassa
viru
encapsul
vrp
particl
immunogen
protect
mice
result
induct
crossreact
multifunct
cell
respons
chahal
et
al
demonstr
mous
model
modifi
dendrim
nanoparticl
mdnp
base
rna
replicon
vaccin
platform
provid
protect
lethal
influenza
ebola
viru
infect
elicit
antibodi
cell
respons
zika
viru
howev
far
selfamplifi
mrna
vaccin
test
clinic
studi
safeti
toler
efficaci
human
yet
proven
varieti
preclin
studi
demonstr
abil
nonrepl
mrna
vaccin
induc
immun
respons
confer
protect
pathogen
pandem
potenti
zikv
ebov
influenza
importantli
approach
current
test
clinic
trial
pardi
et
al
demonstr
id
immun
lnpencapsul
modifi
mrna
encod
prme
glycoprotein
zikv
elicit
potent
durabl
neutral
antibodi
respons
protect
mice
nhp
subsequ
studi
richner
et
al
show
im
administr
similarli
design
zikv
vaccin
result
high
level
neutral
antibodi
titer
protect
confer
steril
immun
restrict
utero
transmiss
zikv
mice
phase
iii
random
placebocontrol
doserang
studi
zikv
mrna
vaccin
initi
decemb
estim
primari
complet
date
septemb
tabl
context
ebolaviru
vaccin
lnpencapsul
modifi
mrna
encod
ebov
gp
deliv
im
shown
induc
ebovspecif
igg
neutral
antibodi
respons
protect
guinea
pig
lethal
infect
sign
clinic
ill
howev
clinic
studi
employ
mrna
vaccin
context
ebola
viru
initi
sever
studi
demonstr
abil
mrna
vaccin
elicit
protect
immun
respons
influenza
petsch
et
al
first
demonstr
id
administr
protaminecomplex
nonrepl
sequenceoptim
mrna
vaccin
encod
influenza
ha
protect
mice
upon
homolog
challeng
influenza
immunogen
ferret
pig
furthermor
compar
ha
encod
vaccin
deliv
im
lnp
formul
elicit
function
antibodi
respons
nhp
remain
stabl
durat
one
year
hi
titer
remain
surrog
measur
protect
human
recent
publish
studi
evalu
efficaci
lnpformul
mrna
vaccin
featur
modifi
nucleotid
encod
ha
protein
potenti
pandem
influenza
subtyp
singl
low
dose
mrna
vaccin
appli
id
im
protect
mice
lethal
homolog
challeng
reduc
lung
viral
titer
observ
upon
singledos
id
immun
ferret
use
nhp
mrna
vaccin
test
dose
rang
gener
robust
hi
titer
singl
im
id
immun
boost
follow
second
vaccin
howev
upon
immun
nhp
receiv
dose
experienc
system
symptom
eg
warm
touch
pain
inject
site
inject
site
irrit
case
decreas
food
consumpt
resolv
within
day
interim
result
phase
firstinhuman
random
doubleblind
placebocontrol
doserang
studi
mrna
vaccin
administ
im
dose
healthi
adult
subject
show
high
seroconvers
rate
demonstr
robust
prophylact
immun
human
tabl
advers
event
mild
moder
sever
nonseri
event
note
clinic
studi
test
efficaci
compar
mrna
vaccin
format
chikungunya
current
ongo
estim
primari
complet
date
septemb
respect
howev
detail
studi
avail
yet
overal
data
show
nonrepl
lnpencapsul
mrna
vaccin
induc
function
antibodi
titer
level
associ
protect
accept
toler
profil
upon
parenter
administr
futur
studi
employ
lnp
encapsul
nonrepl
mrna
target
divers
complex
antigen
requir
demonstr
broad
applic
vaccin
platform
pathogen
pose
potenti
pandem
threat
pandem
hiv
ebola
zika
rais
awar
global
threat
human
health
pose
known
well
newli
emerg
pathogen
provid
impetu
prepar
futur
pandem
promot
develop
vaccin
platform
tackl
challeng
outbreak
situat
new
platform
viral
vector
nucleic
acid
base
vaccin
meet
prerequisit
provid
solut
challeng
repres
highli
versatil
technolog
allow
fast
vaccin
manufactur
vaccin
technolog
advantag
disadvantag
relat
abil
induc
certain
immun
respons
manufactur
capac
safeti
human
use
tabl
viral
vector
base
vaccin
abl
induc
potent
immun
respons
encod
target
antigen
inde
number
clinic
trial
demonstr
viral
vector
base
vaccin
vsvzebov
show
great
promis
induc
protect
respons
human
howev
antigen
deliveri
context
unrel
viru
render
technolog
rel
complex
term
manufactur
furthermor
presenc
immun
target
target
antigen
lead
unfavor
effect
preexist
immun
hamper
immun
respons
seen
vector
inabl
use
technolog
repeat
vaccin
addit
deliveri
attenu
viral
vector
rais
safeti
concern
due
risk
advers
event
residu
viral
replic
upon
deliveri
detect
small
number
subject
clinic
trial
test
vsvzebov
dna
base
vaccin
offer
advantag
allow
rel
simpl
fulli
synthet
product
process
presenc
nonfunct
sequenc
origin
dna
vector
rais
regulatori
safeti
concern
newer
develop
allow
minim
construct
exclus
encod
target
antigen
sever
studi
demonstr
safeti
dna
vaccin
human
use
clinic
trial
test
vaccin
influenza
zika
furthermor
highlight
speed
vaccin
develop
support
technolog
howev
potenti
long
term
persist
genom
integr
depend
inject
devic
electropor
repres
import
disadvantag
technolog
especi
earli
clinic
studi
test
dna
base
vaccin
yield
somewhat
discourag
result
term
immunogen
newer
trial
studi
test
dna
vaccin
zika
viru
demonstr
technolog
abl
induc
promis
immun
respons
like
dna
vaccin
rna
base
vaccin
technolog
support
compar
simpl
fulli
synthet
manufactur
process
allow
product
differ
vaccin
use
establish
product
process
facil
inabl
genom
integr
lack
persist
cell
vaccine
offer
import
advantag
term
vaccin
safeti
howev
sinc
rna
vaccin
repres
recent
develop
technolog
describ
use
human
less
well
character
viral
vector
dna
base
vaccin
although
studi
requir
fulli
character
technolog
human
clinic
studi
conduct
far
yield
overal
encourag
result
term
safeti
immunogen
provid
support
clinic
explor
seem
unlik
singl
technolog
abl
provid
solut
futur
outbreak
situat
combin
present
knowledg
ongo
develop
grow
understand
human
immunolog
provid
tool
success
combat
emerg
global
threat
sr
ej
ks
bp
employ
curevac
ag
